Department of Internal Medicine, J.W. Goethe University Hospital, Frankfurt/Main; Department of General, Visceral, Transplant- and Thoracic Surgery, J.W. Goethe University Hospital, Frankfurt/Main; Dr. Senckenberg Institute for Pathology, University Hospital Frankfurt, Goethe University Frankfurt am Main.
Dtsch Arztebl Int. 2023 Oct 27;120(43):729-735. doi: 10.3238/arztebl.m2023.0195.
Ampullary or papillary carcinoma is a malignant tumor arising from the mucosa in the region of the major duodenal papilla, also known as the ampulla of Vater. Uniform treatment recommendations are lacking both for the adjuvant situation and for palliative care.
A selective literature search was carried out in PubMed in order to identify the most informative publications concerning the epidemiology, clinico-pathological background, and surgical and medical treatment of this condition.
Ampullary carcinoma has an incidence of 0.5 to 0.9 per 100 000 persons and a poor prognosis, with a 5-year survival rate of 41% to 45% for locally confined and 4% to 7% for metastatic disease. Most such tumors are of an intestinal or a pan - creaticobiliary immunohistochemical subtype; the latter has a worse prognosis (median survival, 72-80 vs. 33-41 months). Targeted treatment is not yet available for either subtype, nor is there enough scientific evidence available for the formulation of specific therapeutic recommendations in either the adjuvant or the palliative situation. The treatment of choice for ampullary carcinoma is radical oncological resection of the head of the pancreas with systematic lymphadenectomy. Five-year overall survival is between 10% and 75% depending on the stage. No definitive recommendation for adjuvant therapy can be given. Palliative therapy can be oriented to the published treatment strategies for cancer of the colon, pancreas, and bile duct.
The current state of the evidence on the treatment of ampullary carcinoma is poor. Therapeutic decisions should be discussed in an interdisciplinary tumor board and should, in our opinion, take the histological subtype into account.
壶腹或乳头癌是一种起源于十二指肠乳头区域黏膜的恶性肿瘤,也称为 Vater 壶腹。对于辅助治疗和姑息治疗,缺乏统一的治疗建议。
在 PubMed 上进行了选择性文献检索,以确定有关该疾病的流行病学、临床病理背景以及手术和药物治疗的最具信息性的出版物。
壶腹癌的发病率为每 100000 人 0.5 至 0.9 例,预后较差,局部局限的 5 年生存率为 41%至 45%,转移性疾病的 5 年生存率为 4%至 7%。大多数此类肿瘤为肠型或胰腺胆管免疫组织化学亚型;后者预后较差(中位生存期为 72-80 个月与 33-41 个月)。目前还没有针对任何亚型的靶向治疗方法,也没有足够的科学证据来制定辅助或姑息治疗的具体治疗建议。壶腹癌的治疗选择是根治性胰腺头切除术伴系统淋巴结清扫术。5 年总生存率取决于分期,在 10%至 75%之间。不能明确推荐辅助治疗。姑息治疗可以针对结肠癌、胰腺癌和胆管癌的已发表治疗策略进行。
目前关于壶腹癌治疗的证据状况不佳。治疗决策应在多学科肿瘤委员会中进行讨论,并且我们认为应考虑组织学亚型。